Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerg

Lung Cancer

Floxacin Antibiotics May Augment Treatment of Lung and Bladder Cancers by Inhibiting RSK4

Andrea S. Blevins Primeau, PhD, MBA

August 3, 2021

RSK4-targeting floxacins could boost the efficacy of chemotherapy.

A liquid biopsy or simple blood test can reliably and swiftly genotype 2 key genes associated with a

Lung Cancer

Severe Lymphopenia Associated With Shorter PFS in Unresectable, Stage III NSCLC

Andrea S. Blevins Primeau, PhD, MBA

April 5, 2021

A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.

Needs-assessment survey identifies knowledge gaps of novel therapeutics for CACS

Lung Cancer

Palliative Care Considered Beneficial, Though Infrequently Used in Lung Cancer

Andrea S. Blevins Primeau, PhD, MBA

March 16, 2021

A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.

Lung Cancer

Patient-Reported Outcomes With Lorlatinib in NSCLC

Andrea S. Blevins Primeau, PhD, MBA

March 9, 2021

Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.

Lung Cancer

Durvalumab After Chemoradiotherapy Cost-Effective for NSCLC

Andrea S. Blevins Primeau, PhD, MBA

March 8, 2021

The addition of durvalumab after chemoradiotherapy for treatment of stage III NSCLC was cost-effective compared with chemoradiotherapy alone.

There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.

Lung Cancer

Early Blood-Based Detection of Lung Cancer Possible With Targeted Methylation Panels

Andrea S. Blevins Primeau, PhD, MBA

March 2, 2021

Study data presented at the 2020 World Conference on Lung Cancer in Singapore illustrate the utility of a 10-marker methylation panel in lung cancer.

Lung Cancer

Nivolumab Significantly Improves Survival in Relapsed Malignant Mesothelioma

Andrea S. Blevins Primeau, PhD, MBA

March 1, 2021

Dean Fennell, MBBS, PhD, presented data from a preliminary analysis of the phase 3 CONFIRM trial at the 2020 World Conference on Lung Cancer in Singapore.

Lung Cancer

Nab-Paclitaxel Inferior to Docetaxel in Previously Treated NSCLC

Andrea S. Blevins Primeau, PhD, MBA

February 18, 2021

The aim of the phase 3 J-AXEL trial was to confirm nab-paclitaxel’s noninferiority to docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).

Race and ethnicity were key data points collected from the cohort and tracked with outcomes.

Lung Cancer

CT-Guided Localization of Multiple Lung Modules Feasible With Microcoil Before VATS

Andrea S. Blevins Primeau, PhD, MBA

February 16, 2021

Investigators evaluated the safety and feasibility of microcoil in simultaneous localization for multiple pulmonary nodules before video-assisted thoracic surgery (VATS).

The FDA has approved the first blood-based genetic test that can detect EGFR gene mutations in non-s

Lung Cancer

Corticosteroid Use to Manage irAEs Does Not Affect Survival in NSCLC

Andrea S. Blevins Primeau, PhD, MBA

February 5, 2021

This study characterizes the effect of corticosteroid use for immune-related adverse event (irAE) management on survival in patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy.

Next post in Lung Cancer